Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib/Binimetinib Continuation Sub-Study
PACTR202605826796503Phase 3Unknown
- Sponsor
- Pfizer
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of encorafenib and binimetinib in cancer, sponsored by Pfizer. Status: unknown.
02
Drugs
encorafenibbinimetinib
03
Conditions
cancer
Beyond the preview
Go deeper on PACTR202605826796503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605826796503.